Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer by Watters, A D et al.
Genetic aberrations of c-myc and CCND1 in the development of
invasive bladder cancer
AD Watters
1, Z Latif
1, A Forsyth
1, I Dunn
2, MA Underwood
1, KM Grigor
3 and JMS Bartlett*
,1
1University Department of Surgery, Level II, Queen Elizabeth Building, Glasgow Royal Inﬁrmary, Glasgow G31 2ER, UK;
2Department of Surgery, Southern
General Hospital, Glasgow, UK;
3University Department of Pathology, Western General Hospital, Edinburgh EH4 2XU, UK
Detrusor muscle invasive transitional cell carcinoma is associated with poor prognosis and is responsible for the majority of
bladder cancer related deaths. Ampliﬁcations of c-myc and CCND1 are associated with detrusor-muscle-invasive transitional
cell carcinoma, however, their precise role in driving disease progression is unclear. Fluorescence in situ hybridisation on
archival tissue from 16 patients with primary diagnosis of 5pT2 transitional cell carcinoma and 15 cases with primary pTa/pT1
disease subsequently progressing to detrusor-muscle-invasion was performed, in the latter group both pre and post muscle
invasive events were studied. No patients presenting with 5pT2 had ampliﬁcation of c-myc, two out of 16 (12.5%) had
CCND1 ampliﬁcation. Of patients who developed 5pT2, two out of 15 (13.3%) had ampliﬁcation of c-myc, both in 5pT2,
ﬁve out of 15 (33.3%) had CCND1 ampliﬁcation, two in pTa/pT1 tumours, three in 5pT2 transitional cell carcinomas. In total,
two out of 31 (6.5%) of patients’ 5pT2 TCCs were ampliﬁed for c-myc and six out of 31 (19%) were ampliﬁed for CCND1.
Eighty-seven per cent (40 out of 46) of tumours were polysomic for chromosome 8 and 80% (37 out of 46) were polysomic
for chromosome 11 and this reﬂected the high copy numbers of c-myc and CCND1 observed. In almost all cases an increase
in c-myc/CCND1 copy number occurred prior to invasion and persisted in advanced disease. Ampliﬁcation of CCND1 or
alterations in c-myc/CCND1 early in bladder cancer may have clinical relevance in promoting and predicting progression to
detrusor-muscle-invasive transitional cell carcinoma.
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Muscle invasive transitional cell carcinoma (TCC) of the urinary
bladder (characterised by invasion to the detrusor-muscle wall of
the bladder or beyond) has a poor prognosis. Invasive TCC is
routinely treated with radiotherapy or surgery but, despite treat-
ment, up to 50% of patients develop metastases and die within 5
years (reviewed by van der Meijden, 1998). A large number of
studies have attempted to identify which molecular markers may
be driving progression, ultimately to develop targeted therapies
(reviewed by Unwin et al, 1999; Reznikoff et al, 2000; Witjes et
al, 2000). Cell cycle regulators such as p53 and Rb have been impli-
cated in bladder cancer progression (reviewed by Knowles, 1999).
Previous research within this laboratory demonstrated that polys-
omy of chromosomes 9, 7 and 17 are associated with recurrence
(Bartlett et al, 1998, Watters et al, 2000), but that these genetic
events are not linked with polyploidy (Bartlett et al, 1999). A small
study within this laboratory investigating the drug metabolising
enzyme NAT2 (the gene is located at chromosome 8p22) in TCC
recurrence or progression suggested that polysomy 8 was associated
with disease progression (Watters et al, 2001). Further research
showed an association with polysomy of one or eight in preinvasive
TCCs associated with subsequent invasion (Watters et al, 2002).
Gene ampliﬁcation has been postulated as a mechanism driving
progression in many carcinomas. c-myc, located at 8q24, encodes
for a nuclear transcription factor that regulates cell proliferation
and differentiation (Visscher et al, 1997). Gene ampliﬁcation or
increased copy number of c-myc has been reported in breast
(Visscher et al, 1997), head and neck and ovarian cancer (Sauter
et al, 1995). There has been a suggestion that gain of chromosome
8q is involved in progression in bladder cancer (Sauter et al, 1995).
8q24 gains have been associated with advanced stage and grade
bladder cancer (Wagner et al, 1997). Low rates of ampliﬁcation
(15%) at the 11q13 region have been reported in bladder cancer
(reviewed by Schuuring, 1995). CCND1 maps to 11q13 (Bringuier
et al, 1996), involved in the regulation of the G1/S phase transition
of the cell cycle (Bringuier et al, 1996).
Following on from previous studies within this laboratory
(Bartlett et al, 1998, 1999; Watters et al, 2000, 2001) which asso-
ciated speciﬁc chromosomal aberrations with recurrence or
progression, we hypothesised that alteration of key cell cycle modu-
lators c-myc and CCND1 via gene alterations drives progression of
superﬁcial and locally invasive TCC (pTa/pT1). This study deter-
mined chromosome and gene copy number by FISH in a cohort
of patients with either detrusor muscle invasive TCC at presenta-
tion or who developed detrusor muscle invasive TCC following a
presentation with non-muscle invasive (pTa/pT1) TCC.
MATERIALS AND METHODS
Patients
Sixteen patients with 5pT2 disease and seven with pTa and
eight with pT1 disease that progressed to 5pT2 were identiﬁed
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Glasgow Royal Inﬁrmary. Patients were categorised into two
groups: PP (progressed at presentation; patients with 5pT2 at
initial diagnosis) and RP (recurrent and progressive; patients
with pTa/pT1 disease at initial diagnosis who subsequently
recurred and progressed with their disease). In order to attempt
to understand the genetic events underlying progression from
pTa or pT1 TCC, the pre and post muscle-events were studied
in the RP group; the presenting lesion in the PP group. This
approach was based on previous research within this laboratory
that demonstrated that there was a considerable increase in
genetic aberrations from patients with a primary pTa or pT1
TCC that progressed to detrusor-muscle-invasion when
compared to those with non-invasive recurrences (Watters et
al, 2002).
A total of 46 tumours were studied. Five micron formalin ﬁxed
parafﬁn processed tissue sections of each tumour were cut onto
sialinised slides and baked at 568C overnight. All TCCs analysed
had a representative section stained with haematoxylin and eosin
and were restaged and regraded by a specialist urological patholo-
gist (KMG) following current UICC guidelines (Sobin and
Wittekind, 1995).
Fluorescence in situ hybridisation (FISH)
To determine gene and chromosome copy numbers, levels of gene
ampliﬁcation or deletion in situ, FISH, using locus speciﬁc DNA
probes for c-myc, CCND1 and chromosome enumeration probes
for eight and 11 in a dual hybridisation reaction, was applied
to ﬁve micron tissue sections of tumour. Included in each run
was bladder tissue with normal copy number for all the probes
used.
The FISH methodology was followed as outlined: Tissue sections
were dewaxed and rehydrated, then subjected to pretreatments
0.2 N HCl for 20 min at room temperature, 8% sodium thiosul-
phate at 808C for 30 min and 0.5% pepsin in 0.2 N HCl for
26 min at 378C. Tissue sections were post-ﬁxed in 10% neutral
buffered formalin at room temperature for 10 min before dehydra-
tion in ascending grades of alcohol and air drying. These steps were
carried out on a VP2000 robotic pretreatment slide processor
(Vysis, UK, Ltd).
The tissue sections were assessed for extent of digestion as
previously outlined (Watters et al, 2000). Tissue sections were
denatured in 70% formamide, 26SSC pH 7–8 at 728C for
5 min on the Omnislide hybridisation module (Hybaid, UK
Ltd), dehydrated and air-dried. Two separate experiments were
carried out on adjacent sections, with probes for the pericentro-
mere of chromosome 8, labelled with SpectrumGreen
TM and a
SpectrumOrange
TM labelled probe for c-myc (Vysis, UK). The
alternative probes set was probes for the pericentromere of chro-
mosome 11, labelled with SpectrumGreen
TM and a
SpectrumOrange
TM labelled probe for CCND1 (Vysis, UK). Both
combinations were applied as a double label. For each section,
1 ml of each probe was added to 7 ml hybridisation mix (50%
formamide, 26SSC, 10% dextran sulphate) and 1 ml deionised
water and denatured in a waterbath at 728C for 5 min, applied
to the tissue sections and hybridised overnight at 378C (Vysis,
Inc).
Following posthybridisation washes in 0.46SSC, 0.3% Nonidet
30, pH 7 at 728C for 2 min, the tissue sections were mounted in
0.25 mgm l
71 DAPI in antifade (Vectashield, UK) and viewed
with a Leica DMLB microscope. A triple band pass ﬁlter block
spanning the excitation and emission wavelengths of the Spec-
trumGreen
TM and SpectrumOrange
TM ﬂuors (Vysis, UK) and
DAPI was used in the analysis of the hybridisation. Image capture
was achieved using a digital camera and software (Leica DC200,
Leica UK).
Scoring criteria
Serially sectioned haematoxylin and eosin stained tissue sections
were ﬁrst examined microscopically to localise areas of TCC. FISH
stained sections were then scanned at 6400 magniﬁcation to loca-
lise the TCC areas identiﬁed. Three distinct areas were identiﬁed
and signals per nucleus in 20 nuclei per area for chromosome 8
and c-myc and chromosome 11 and CCND1 respectively were
counted at 61000 magniﬁcation and the results recorded manu-
ally. Average chromosome and gene copy number per area was
calculated by totalling the number of signals counted and dividing
this ﬁgure by the number of nuclei assessed. Mean copy number
per section was calculated by combining the results for the three
areas. Where chromosomal heterogeneity was noted the most
abnormal score was used in the ﬁnal analysis. Control sections
from normal bladder tissue obtained from post mortem normal
bladder were included in the analysis. Values for disomy were
derived from the analysis of these tissue sections as previously
reported (Bartlett et al, 1998; Watters et al, 2000).
The ratio of gene to chromosome copy number was determined
by dividing the number of signals for c-myc or CCND1 by the
number of signals for chromosome 8 or 11 respectively. Gene
ampliﬁcation was deﬁned as a ratio greater than two, based on
values determined by Vysis Inc and incorporated in their guidelines
for using the PathVysion
TM system to determine ampliﬁcation
levels of the HER2/neu gene in breast cancer in a diagnostic setting
(Bartlett et al, 2001). This was based on the normal mean copy
number for the gene as being less than four signals per nucleus.
In some cases with high ampliﬁcation ratios (45 copies per chro-
mosome), clusters of gene signals, analogous to homogeneous
staining regions, were observed. In these cases it was not possible
to accurately assess the true gene copy number, but by focusing
through the cluster a reasonable estimate was achieved. In none
of these cases did the presence of a cluster of signals alter the ﬁnal
result.
Statistics
Crosstabs (SPSS for windows release 9.0) was used to compare
similarity of copy number between chromosomes 8 and 11 and
c-myc and CCND1.
RESULTS
Patients
The average age of the PP group was 70.9 years, (range 50 to 89
years) and the RP group 68.9 years (range 43 to 84 years). The
M:F ratio was 13:3 in the PP group, 12:3 in the RP group. Mean
follow-up for the PP group was 42 months (range 6–91) and for
the RP group 39 months (range 3–117). In the PP group, 13
patients were treated with radiotherapy, one died before radiother-
apy commenced, one refused radiotherapy and one had a
cystectomy. In the RP group, six had radiotherapy after the
muscle-invasive event, ﬁve had a cystectomy, two had no treat-
ment. One patient had palliative radiotherapy early in his disease
history, subsequently recurred with pT1 and pTa TCCs and even-
tually, 13 years later, succumbed to his disease, and one patient had
radiotherapy before his muscle-invasive TCC. Of the PP group, 11
patients died from their disease, range 6 to 59 months following
diagnosis. The four patients still alive had no evidence of local
or metastatic disease at last clinic appointment. Of the RP group
9 patients died of their disease, range 3–15 months following diag-
nosis of invasive disease. Of the six patients still alive, two had no
evidence of local or metastatic disease at last clinic appointment,
two had metastatic disease, and there were no records following
diagnosis with invasive TCC for the remaining two.
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All hybridisations were successful apart from that of one PP with
the probes for c-myc and chromosome 8. The normal range for
copy number of each DNA probe is detailed in Table 1, and an
example of a TCC with disomy of c-myc and chromosome 8 is
shown in Figure 1A.
c-myc and chromosome 8
Fourteen out of 15 (93%) PP tumours had increased copy number
of c-myc and chromosome 8, between 2.15 and 6.35 for c-myc and
between 2.03 and 7.73 for chromosome 8 (Figure 1B). None of the
tumours exhibited gene ampliﬁcation (Table 2).
Twenty-seven out of 30 (90%) RP tumours had increased copy
number for c-myc of between 2.03 and 5.53. Of these 14 out of
15 (93%) were abnormal in the pTa and pT1 TCCs, the TCC
was pTa and 13 out of 15 (87%) were abnormal in the 5pT2
TCC (Table 2). Twenty-seven out of 30 (90%) RP tumours had
polysomy 8, (range 2.05 to 4.89). Of these 13 out of 15 (87%)
were polysomic in the pTa or pT1 TCCs , both normal TCCs
were pTa and 14 out of 15 (93%) were polysomic in the pT2+
TCC. Two out of 30 (6.7%) tumours had gene ampliﬁcation,
and both were 5pT2.
There was a close correlation between c-myc and chromosome 8
copy number, P=0.001.
CCND1 and chromosome 11
Fourteen out of 16 (87.5%) PP tumours had an increase of
CCND1, copy number between 2.70 and 13.18 (Table 2) and 12
out of 16 (75%) had polysomy 11, copy number between 2.70
and 5.88 (Figure 1C). Of these, two (12.5%) had ampliﬁcation of
CCND1 (Table 2, Figure 1D).
Twenty-four out of 30 (80%) RP tumours had an increase in
CCND1 (range 2.11 to 9.00, Table 2). Of these 12 out of 15
(80%) were abnormal in the pTa or pT1 TCCs; two of the normal
tumours were pTa, one was pT1, and 12 out of 15 (80%) were
abnormal in the pT2+ TCC. Twenty-three out of 30 (77%) RP
tumours were polysomic for chromosome 11, copy number
between 2.13 and 4.57. Of these 11 out of 15 (73%) were polyso-
mic in the pTa or pT1 TCC; three of the normal TCCs were pTa,
one was pT1, and 12 out of 15 (80%) were polysomic in the pT2+
TCC. Six out of 30 (20%) tumours had ampliﬁcation of CCND1,
four of which were pT2 or above, the remaining two were
pT1G3 and pTaG3. Of these one patient had ampliﬁcation in their
pre and post muscle invasive tumours. There was a close correla-
tion with CCND1 and chromosome 11 copy number, P50.001.
In total six out of 31 patients (19%) had ampliﬁcation of
CCND1 in their detrusor muscle invasive tumours, compared to
two out of 31 (6.5%) patients with ampliﬁcation of c-myc, N/S.
Both patients with ampliﬁcation of c-myc had ampliﬁcation of
CCND1.
Data from the results of the assessment of gene copy number in
the non-muscle invasive (pTa or pT1) TCCs is depicted in Table 3.
This shows similar rates of increased copy number in pTa or pT1
tumours.
DISCUSSION
The observation that ampliﬁcation of oncogenes predominates in
later stages of cancer progression (Ried et al, 1999; Reznikoff et
al, 2000) and that the majority of genetic alterations in TCC occur
prior to progression (Tsao et al, 2000) implies that genetic instabil-
ity of this type may inﬂuence progression. The aim of this study
was to determine if changes of the oncogenes c-myc and CCND1
in preinvasive tumours drive later progression. Abnormal regula-
tion of c-myc can result in phenotypic transformation, aberrant
cell cycle control and genomic instability. Disruption of CCND1,
that encodes for cyclin D1, involved in the regulation of the G1/
S transition of the cell cycle (Bringuier et al, 1996), may form
the basis of genetic instability (Reznikoff et al, 2000).
The small numbers of tumours exhibiting gene ampliﬁcation of
c-myc observed here is in accordance with previous studies
(Sauter et al, 1995). However, rates of ampliﬁcation of CCND1
were 19%, marginally higher than a previous study of bladder
cancer by Southern blotting which reported ampliﬁcation rates
of 11q13 of 11% (Bringuier et al, 1996). The candidate oncogenes
in the region 11q13 in bladder cancer postulated by Bringuier et
al (1996) are CCND1 and EMS1 (a gene involved in regulating
the interactions between components in the adherens junctions,
Schuuring (1995)).
Both the 8q24 (that contains c-myc) and 11q13 regions are
frequently involved in translocations in lymphomas (Arber,
2000). Burkitt’s lymphoma is usually associated with a translo-
cation of c-myc and CCND1 has been suggested as a marker
for mantle cell lymphoma (Arber, 2000). Although transloca-
tions are not uncommon in bladder cancer, translocation as a
sole cytogenetic event has not been described (Sandberg and
Berger, 1994). However, the chromosomal regions that contain
c-myc and CCND1 are genetically unstable, which may be of
signiﬁcance in the development of muscle-invasive bladder
cancer.
Previously, research from this laboratory has shown an
observed increase in aneusomy from pTa to pT1 TCCs, but a
lack of association with stage and recurrence or progression,
suggesting that it is aneusomy and not pathological classiﬁcation
which is driving progression in pTa or pT1 tumours (Watters et
al, 2001, 2002; Edwards et al, 2001). Furthermore, it is of inter-
est to note that the rate of genetic abnormalities is similar when
comparing the data from patients who progress from non-
muscle-invasion and those who present with muscle invasion.
In this study, and previously, we have shown that there are high-
er rates of aneusomy in patients who progress to muscle
invasion compared to those who recur with pTa/pT1 disease
(Watters et al, 2000, 2001, 2002). Muscle-invasive TCCs are
characterised by a large number of cytogenetic alterations includ-
ing overrepresentation of 8q and 11q13 (Tomovska et al, 2001).
Thus this study would support the ﬁnding by Tsao et al (2000)
that the majority of genetic alterations in TCC occur prior to
progression. They showed that there was an increase of only
10% of genetic aberrations in metastases compared to primary
cell lines from two patients reported in their study, and they
suggest that most allelic losses occur before progression. It is
widely recognised that genetic instability increases from precur-
sor, or in the case of TCC, preinvasive lesions, to invasion
(Ried et al, 1999). In our study we also observed that there
was a very high rate of abnormalities in preinvasive lesions,
regardless of stage.
A gain of chromosome 8q may contribute to bladder cancer
progression (Sauter et al, 1995). The gain of a large fragment of
8q also known as an isochrome 8q has been observed in bladder
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Table 1 Normal values for chromosome and gene copy number
Probe Copy number Normal range
c-myc 1.70+0.03 1.61 to 1.79
Chromosome 8 1.76+0.08 1.52 to 2.00
CCND1 1.74+0.11 1.41 to 2.07
Chromosome 11 1.72+0.13 1.33 to 2.11
Values for normal copy number were ﬁrst established by evaluating normal bladder
tissue. The normal range for disomy was deﬁned as the mean+36s.d. (99% CI).
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from pT1 to pT2–4 than from pTa to pT1 could suggest that
8q gains occur later in bladder cancer progression than 8p dele-
tions (Wagner et al, 1997). In a study of chromosomal
aberrations by comparative genomic hybridisation, there was a very
small percentage of gains of 11q13 in pTa tumours. However, in
pT1 tumours, loss of chromosome 11 was observed with the excep-
tion of 11q13 which was often gained or ampliﬁed (Simon et al,
1998). In this study, c-myc and CCND1 may be dysfunctional
due to the observed increased copy number, and it is possible that
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Figure 1 FISH size bar on all photomicrographs is 20 microns. Chromosome copy depicted in green, gene copy in red, nuclei stained with DAPI, ﬂuor-
escing blue. (A) Disomy of c-myc and chromosome 8, PP pT2 G3. (B) Polysomy of c-myc and chromosome 8, RP pT1cG3. (C) Polysomy of CCND1 and
chromosome 11, RP, pT2G3. (D) Ampliﬁcation of CCND1, RP, pT2G3.
Table 2 Percentage of TCCs with increased gene copy number for c-myc and CCND1
Patient
group Stage
Increased c-myc
copy number c-myc amp
Increased CCND1
copy number CCND1 amp
PP pT2 14/15 (93%) 0 14/16 (87.5%) 2/16 (12.5%)
RP pTa/pT1 14/15 (93%) 0 12/15 (80%) 2/15 (13%)
RP pT2 13/15 (87%) 2/15 (13%) 12/15 (80%) 4/15 (27%)
PP=progressed at presentation, patients with 5pT2 at initial diagnosis; RP=recurrer progressors, patients with
pTa/pT1 disease at initial diagnosis who subsequently recurred and progressed with their disease; amp=gene
ampliﬁcation. There was a high percentage of tumours with elevated gene copy number but no signiﬁcant
differences between the patient groups. Of those with elevated gene copy number, a small proportion also
had gene ampliﬁcation.
Table 3 Comparison of rates of increased gene copy number and gene
ampliﬁcation between stage pTa and pT1
Stage
Increased c-myc
copy number
Amp
c-myc
Polysomy
CCND1
Increased CCND1
copy number
pTa 6/7 0 4/7 1/15
pT1 8/8 0 7/8 1/15
This table illustrates the rates of anuesomy and ampliﬁcation in patients with pTa
or pT1 TCCs that represented with detrusor-muscle-invasion (5pT2). Rates were
similar for either pTa or pT1 TCCs.
c-myc and CCND1 in bladder cancer
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route to muscle-invasion.
When the results from this study were compared to a previous
study in this laboratory that examined HER2/neu and chromosome
17 levels in TCC (unpublished data), very similar results were
obtained i.e high levels of polysomy and much lower levels of
ampliﬁcation. This suggests that tumours that progress to pT2
and above, or present with that phenotype, have high levels of
polysomy of many chromosomes, and that they may exhibit poly-
ploidy. However, we have investigated, by the use of multiple FISH
probes, the rate of polysomy in this cohort and have found that
this cannot explain the ﬁndings in this study (Bartlett et al,
1999). Therefore we conclude that the alterations in these chromo-
somes represent events which are closely associated with disease
progression and independent of polyploidisation. Ried et al
(1999) noted that the number of chromosomal copy alterations
increased signiﬁcantly in the transition from precursor lesions to
invasive carcinomas, reﬂecting an overall genetic instability which
we have also observed here.
Further studies of gene alterations in non-invasive non progres-
sive patient groups and investigations of protein expression are
required to clarify the effects of genetic abnormalities of c-myc
and CCND1 on progression of TCC. Nevertheless, this study has
added to the growing evidence that genetic alterations prior to
detrusor muscle invasion delineate those cancers which will
progress and by extension these changes are associated with genes
which therefore drive progression.
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